File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Lamivudine in hepatitis B-associated membranous nephropathy

TitleLamivudine in hepatitis B-associated membranous nephropathy
Authors
Issue Date2006
PublisherFederation of Medical Societies of Hong Kong
Citation
Hong Kong Society of Nephrology Annual Scientific Meeting, Hong Kong, 10-11 September 2005. In The Hong Kong Medical Diary, 2006, v. 11 n. 5, p. 21 How to Cite?
AbstractBackground: Although lamivudine is effective for the treatment of chronic hepatitis B (HBV) infection, its potential therapeutic impact on HBV-related membranous nephropathy (MN) in adults has not been characterised. Methods: We treated 10 HBsAg-positive patients with biopsy-proven MN, elevated serum alanine aminotransferase (ALT), and HBVDNAemia (group 1), and compared their clinical course with 12 patients diagnosed to have HBV infection, elevated serum ALT, and MN in the pre-lamivudine era (group 2). Results: Baseline demographic and clinical parameters were not significantly different between the 2 groups. In group 1, lamivudine treatment was associated with significant reduction in proteinuria, increase in serum albumin, normalisation of ALT levels and disappearance of circulating HBV-DNA during the first year. Four (40%) and six (60%) patients went into complete remission (proteinuria < 0.3 g/day) at 6 and 12 months, respectively. In group 2, significant proteinuria persisted during the first year. One (8.3%) and three (25%) patients went into remission. Cumulative 3-year renal survival (using endstage renal disease as the primary end point) was 100% in group 1 and 58% in group 2 (p = 0.024, log rank test). Blood pressure control reached the target of < 130/85 mmHg in both groups. Lamivudine was well tolerated and not associated with any adverse events. Hepatic decompensation or malignancy was not observed during follow up in both groups. Conclusion: HBV-related MN led to end-stage renal disease in a significant proportion of patients before the advent of anti-viral therapy. Lamivudine treatment improves renal outcome in HBV carriers with MN and evidence of liver disease.
Persistent Identifierhttp://hdl.handle.net/10722/101235
ISSN

 

DC FieldValueLanguage
dc.contributor.authorTang, Sen_HK
dc.contributor.authorLai, FMen_HK
dc.contributor.authorLui, RYHen_HK
dc.contributor.authorTang, CSOen_HK
dc.contributor.authorKung, NNSen_HK
dc.contributor.authorHo, YWen_HK
dc.contributor.authorChan, KWen_HK
dc.contributor.authorLeung, JCKen_HK
dc.contributor.authorLai, KNen_HK
dc.date.accessioned2010-09-25T19:41:21Z-
dc.date.available2010-09-25T19:41:21Z-
dc.date.issued2006en_HK
dc.identifier.citationHong Kong Society of Nephrology Annual Scientific Meeting, Hong Kong, 10-11 September 2005. In The Hong Kong Medical Diary, 2006, v. 11 n. 5, p. 21-
dc.identifier.issn1812-1691-
dc.identifier.urihttp://hdl.handle.net/10722/101235-
dc.description.abstractBackground: Although lamivudine is effective for the treatment of chronic hepatitis B (HBV) infection, its potential therapeutic impact on HBV-related membranous nephropathy (MN) in adults has not been characterised. Methods: We treated 10 HBsAg-positive patients with biopsy-proven MN, elevated serum alanine aminotransferase (ALT), and HBVDNAemia (group 1), and compared their clinical course with 12 patients diagnosed to have HBV infection, elevated serum ALT, and MN in the pre-lamivudine era (group 2). Results: Baseline demographic and clinical parameters were not significantly different between the 2 groups. In group 1, lamivudine treatment was associated with significant reduction in proteinuria, increase in serum albumin, normalisation of ALT levels and disappearance of circulating HBV-DNA during the first year. Four (40%) and six (60%) patients went into complete remission (proteinuria < 0.3 g/day) at 6 and 12 months, respectively. In group 2, significant proteinuria persisted during the first year. One (8.3%) and three (25%) patients went into remission. Cumulative 3-year renal survival (using endstage renal disease as the primary end point) was 100% in group 1 and 58% in group 2 (p = 0.024, log rank test). Blood pressure control reached the target of < 130/85 mmHg in both groups. Lamivudine was well tolerated and not associated with any adverse events. Hepatic decompensation or malignancy was not observed during follow up in both groups. Conclusion: HBV-related MN led to end-stage renal disease in a significant proportion of patients before the advent of anti-viral therapy. Lamivudine treatment improves renal outcome in HBV carriers with MN and evidence of liver disease.-
dc.languageengen_HK
dc.publisherFederation of Medical Societies of Hong Kong-
dc.relation.ispartofThe Hong Kong Medical Diaryen_HK
dc.titleLamivudine in hepatitis B-associated membranous nephropathyen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailTang, S: shanwut@yahoo.com.cnen_HK
dc.identifier.emailTang, CSO: csotang@HKUCC.hku.hken_HK
dc.identifier.emailChan, KW: hrmtckw@hku.hken_HK
dc.identifier.emailLeung, JCK: jckleung@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.identifier.hkuros104855en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats